WHAT: Timely discussion of the most pressing issues in our nation's drive to cure cancer, featuring leading experts in cancer treatment, patient care, policy, and drug development. Panelists will examine the most urgent challenges in precision medicine -- from the overwhelming complexity of tumors, to the costs of treatment, to regulatory barriers that impede widespread use -- and the solutions needed to overcome them.
WHO:
Bruce E. Johnson, MD, FASCO, President, ASCO
Robert Califf, MD, Vice Chancellor for Health Data Science, Duke Health; Former FDA Commissioner
Otis Brawley, MD, MACP, FASCO, FACE, Chief Medical Officer, American Cancer Society
Suzanne Topalian, MD, Melanoma Program Director, Johns Hopkins University
Anna B. Berry, MD, Scientific Director, Personalized Medicine Program, Swedish Cancer Institute
Robert Dubois, MD, PhD, Chief Science Officer and Executive Vice President, National Pharmaceutical Council
Barbara L. McAneny, MD, President-Elect, American Medical Association; CEO, New Mexico Oncology Hematology Consultants
Edward S. Kim, MD, Chair of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute; Chair, TAPUR Steering Group
Meg Gaines, JD, Attorney, Survivor and Founder of the Center for Patient Partnerships, University of Wisconsin
Lincoln D. Nadauld, MD, PhD, Medical Director of Cancer Genomics, Intermountain Healthcare
Judy Wilkins, Cancer Survivor
Welcoming remarks by Clifford A. Hudis, MD, FACP, FASCO, Chief Executive Officer, ASCO.
Event moderated by Richard L. Schilsky, MD, FACP, FASCO, Chief Medical Officer, ASCO.
WHEN: Wednesday, January 31, 2018 12:30 pm – 4:00 pm ET
Doors open at 12:30 for lunch and networking; first panel begins at 1:00
